Novel therapeutic advances for uveal melanoma
10.3980/j.issn.1672-5123.2026.5.16
- VernacularTitle:葡萄膜黑色素瘤的治疗新进展
- Author:
Xiaodie LI
1
;
Chaoqun LIU
1
;
Xiaojuan CHENG
1
;
Yuhan SHANG
1
;
Ruixue REN
1
;
Yulu HE
1
;
Xiaoli YANG
1
Author Information
1. North Sichuan Medical College, Nanchong 637000, Sichuan Province, China; Department of Ophthalmology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
- Publication Type:Journal Article
- Keywords:
uveal melanoma;
metastatic uveal melanoma;
systemic prevention and control;
Tebentafusp;
local-systemic synergy;
nanomedicine
- From:
International Eye Science
2026;26(5):823-830
- CountryChina
- Language:Chinese
-
Abstract:
Uveal melanoma(UM)is the most common primary intraocular malignancy in adults, characterized by high invasiveness and unique metastatic biological features. Although local treatments(such as proton beam therapy and brachytherapy)can effectively control the primary lesion, approximately 50% of patients eventually develop distant metastasis, with the liver being the primary target organ(occurring in 90% of cases). This highlights a paradigm shift in treatment focus from mere local control to systemic prevention and management. For metastatic UM(mUM), current treatment strategies encompass biomarker-guided molecular targeted therapy, immunotherapy(including Tebentafusp, vaccines, and oncolytic virus therapy), and liver-directed therapy. Focusing on the synergy between local and systemic prevention and control, this article systematically elaborates on the precision local treatment for primary UM, the decision-making pathway for systemic treatment of metastatic UM based on molecular subtyping, the integration of local and systemic therapies for liver metastases, and the translational value of nanomedicine in addressing therapeutic bottlenecks. It provides insights for optimizing clinical management of mUM and developing novel therapeutic strategies.
